Non-Invasive & Rapid Detection of Bladder Cancer

Currently, there are about 30,000 new cases of bladder cancer every year in Germany. Although 75 % of bladder cancers are superficial and easily treatable by operation, there is a high risk of recurrence. 10-20 % of these recurrence patients experience a progression to muscle-invasive bladder carcinoma which predisposes them to metastasis and a significantly reduced survival rate. Due to the high risk of recurrence, patients are subject to close follow-up care.

According to international guidance, cystoscopy is the gold standard for the diagnostic of bladder cancer but as invasive method it is perceived as very unpleasant and expensive. In addition, low sensitivity of 30 % doesn´t ensure the differentiation between cancer and inflammation.

In this context, the SCIENION GmbH, together with the Institute for prevention and occupational medicine (IPA), develops a non-invasive lateral flow immunoassay, called UROfast, for the rapid and sensitive diagnostic of bladder cancer to improve patients’ survival probability with simultaneous increase in quality of life. The combination of up to 10 biomarkers ensure the early detection as well as the identification of high-grade and muscle-invasive urothelial carcinomas without any inconveniences for the patients.

For this purpose, SCIENION’s unique sciDROP technology for automated precision dispensing was used for the development of the multiplexed biomarker assay that provides an all-in-one measurement within 10-20 min in a lateral flow reader through a kinetic measurement algorithm. As the whole development process accords to the IVDR, the UROfast tests will be suitable for laboratory use as well as for decentralized use in medical practices.

More Customer Spotlights


Printing vascularized skin

Rensselaer Polytechnic Institute has developed a bioink of human cells and animal collagen using CELLINK’s BIO X bioprinter.


Mass Produced Stem Cells – A Gateway to Personalized Medicine

Ronawk mass-produces adult stem cells using bioprinters from CELLINK paving the way for the possibility to grow and transplant patients’ own stem cells without the need for the immunosuppressive drugs that are usually required after an organ donation.

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.